SAN FRANCISCO, May 29 /PRNewswire-FirstCall/ -- Osteologix, Inc. announced that Philip J. Young, its President and Chief Executive Officer, will present an overview of the company and its new product under development for the treatment of osteoporosis later today at the Red Chip Small-Cap Investor Conference at the Ritz Carlton Hotel in San Francisco at 2:45 p.m. Pacific Time. The presentation will be webcast live and will be available at http://www.modavox.com/events/redchip/0507/ssafe/login/login.html. It will also be archived for a limited time after the presentation.
About Osteologix
Osteologix develops proprietary therapeutics for the treatment of important unmet medical needs in bone disease and women’s health. The Company’s lead product, NB S101, is being evaluated in a phase II clinical trial for the treatment of osteoporosis. Based on the Company’s own data as well as data from phase III clinical trials conducted on a similar drug that is approved for sale in Europe, Osteologix believes that NB S101 increases formation of new bone and decreases loss of existing bone. Osteologix further believes that NB S101 will provide patients with greater convenience and fewer side effects than drugs currently approved for osteoporosis in the United States, Europe and elsewhere. Additional information on Osteologix can be obtained on the Company’s website, http://www.osteologix.com.
FORWARD-LOOKING STATEMENTS:
Certain of the statements set forth in this press release constitute “Forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “intend,” “forecast,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “will likely,” “should,” “could,” “would,” “may” or words or expressions of similar meaning. All such forward looking statements involve risks and uncertainties, including, but not limited to: statements regarding Osteologix’s research and development programs; proposed marketing and sales; patents and regulatory approvals; the effect of competition and proprietary rights of third parties; the need for and availability of additional financing and access to capital; and the seeking of joint development, licensing or distribution and collaboration and marketing arrangements with pharmaceutical companies. There can be no assurance that such forward-looking statements will prove to be accurate and Osteologix undertakes no obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements.
Osteologix, Inc.
CONTACT: Philip J. Young, President and Chief Executive Officer, orMatthew M. Loar, Chief Financial Officer, both of Osteologix, Inc.,+1-415-955-2700
Web site: http://www.osteologix.com/
